Senti Biosciences (SNTI) Cash from Operations (2021 - 2025)
Senti Biosciences' quarterly Cash from Operations came in at 6875000.0 in Q4 2025, up 49.09% year-on-year from 4611334.62 in Q4 2024, and up 27.22% quarter-over-quarter from 9446000.0 in Q3 2025.
Senti Biosciences has reported Cash from Operations for 5 years, with the latest figure at 6875000.0 in Q4 2025.
- For the quarter ending Q4 2025, Cash from Operations rose 49.09% year-over-year to 6875000.0; the trailing twelve-month figure through Dec 2025 stood at 43444000.0 (down 4.94% YoY), and the FY2025 full-year result was 43444000.0, down 4.94% from the prior year.
- Cash from Operations for Q4 2025 stood at 6875000.0, up from 9446000.0 in the prior quarter.
- The five-year high for Cash from Operations was 934675.0 in Q2 2021, with the low at 16304000.0 in Q1 2023.
- Average Cash from Operations over 5 years is 9223997.26, with a median of 9446000.0 recorded in 2025.
- Year-over-year, Cash from Operations tumbled 868.08% in 2022 and surged 49.09% in 2025.
- Tracing SNTI's Cash from Operations over 5 years: stood at 1142247.0 in 2021, then plunged by 688.45% to 9006000.0 in 2022, then grew by 21.86% to 7037000.0 in 2023, then slumped by 91.9% to 13504000.0 in 2024, then surged by 49.09% to 6875000.0 in 2025.
- The last three Cash from Operations figures came in at 6875000.0 (Q4 2025), 9446000.0 (Q3 2025), and 13073000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.43 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.08 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.50 Mn |
| 10 | Senti Biosciences Holdings | 22.25 Mn | 22.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -6.88 Mn |
| Dec 31, 2025 | -6.88 Mn |
| Sep 30, 2025 | -9.45 Mn |
| Sep 30, 2025 | -9.45 Mn |
| Jun 30, 2025 | -13.07 Mn |
| Jun 30, 2025 | -13.07 Mn |
| Mar 31, 2025 | -14.05 Mn |
| Mar 31, 2025 | -14.05 Mn |
| Dec 31, 2024 | -13.50 Mn |
| Dec 31, 2024 | -13.50 Mn |
| Sep 30, 2024 | -7.87 Mn |
| Sep 30, 2024 | -7.87 Mn |
| Jun 30, 2024 | -8.35 Mn |
| Jun 30, 2024 | -8.35 Mn |
| Mar 31, 2024 | -11.68 Mn |
| Mar 31, 2024 | -11.68 Mn |
| Dec 31, 2023 | -7.04 Mn |
| Dec 31, 2023 | -7.04 Mn |
| Sep 30, 2023 | -15.38 Mn |
| Sep 30, 2023 | -15.38 Mn |
| Jun 30, 2023 | -13.68 Mn |
| Jun 30, 2023 | -13.68 Mn |
| Mar 31, 2023 | -16.30 Mn |
| Mar 31, 2023 | -16.30 Mn |
| Dec 31, 2022 | -9.01 Mn |
| Dec 31, 2022 | -9.01 Mn |
| Sep 30, 2022 | -10.14 Mn |
| Sep 30, 2022 | -10.14 Mn |
| Jun 30, 2022 | -5.70 Mn |
| Jun 30, 2022 | -5.70 Mn |
| Mar 31, 2022 | -10.06 Mn |
| Mar 31, 2022 | -10.06 Mn |
| Dec 31, 2021 | -1.14 Mn |
| Dec 31, 2021 | -1.14 Mn |
| Sep 30, 2021 | -1.05 Mn |
| Sep 30, 2021 | -1.05 Mn |
| Jun 30, 2021 | -934,675.00 |
| Jun 30, 2021 | -934,675.00 |